用不成比例的危险和治愈率计算样本大小的一般方法
Huan Cheng1, Xiaoyun Li1, Jianghua He2
1BeOne Medicines USA, California, USA.
Pharmaceutical statistics
|July 6, 2025
概括
本研究引入了癌症临床试验的统一样本大小计算方法,考虑到免疫疗法研究中常见的治愈率和不成比例的风险.
科学领域:
- 生物统计学 生物统计学
- 临床试验设计 临床试验设计
- 癌症研究 癌症研究
背景情况:
- 癌症药物开发导致某些患者的长期生存或治愈.
- 免疫疗法试验往往显示出不成比例的危险,如延迟或交叉效应.
- 现有的治愈模型处理治愈率和延迟效果,但需要统一的样本大小计算.
研究的目的:
- 为癌症临床试验中样本大小计算提供统一的方法.
- 整合治愈率模型,并适应不成比例的危险.
- 支持用于分析试验数据的强大统计测试.
主要方法:
- 开发了一种统一的样本大小计算方法.
- 结合了各种治愈率模型和不成比例的危险情景.
- 支持加权罗格兰克测试和Maxcombo测试.
- 使用蒙特卡洛模拟验证了样本大小估计的准确性.
主要成果:
- 拟议的统一方法准确估计了癌症试验的样本大小.
- 该方法在不成比例的危险下显示出强大的性能.
- 蒙特卡洛模拟证实了该方法在各种场景中的准确性.
结论:
- 统一的样本大小计算方法有效地解决了癌症临床试验中的挑战.
- 这种方法通过适应治愈率和不成比例的危险来增强免疫疗法试验设计.
- 该方法为设计癌症临床试验的研究人员提供了可靠的工具.
相关概念视频
Kaplan-Meier Approach
276
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
276
Comparing the Survival Analysis of Two or More Groups
297
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
297
Actuarial Approach
138
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
138
Assumptions of Survival Analysis
199
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
199
Cancer Survival Analysis
457
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
457
Hazard Rate
189
The hazard rate, also known as the hazard function or failure rate, is a statistical measure used to describe the instantaneous rate at which an event occurs, given that the event has not yet happened. From a probabilistic perspective, it represents the likelihood that a subject will experience the event in a very small time interval, conditional on surviving up to the beginning of that interval. In terms of frequency, the hazard rate can be viewed as the ratio of the number of events to the...
189


